化合物 GSK1904529A|T6003|TargetMol

GSK1904529A
1089283-49-7

￥296 1mg 起订

￥698 5mg 起订

￥1120 10mg 起订

上海更新日期：2024-09-29

TargetMol中国（陶术生物）

VIP3年

联系人：邵小姐

手机：4008200310 拨打

邮箱：marketing@tsbiochem.com

产品详情:

中文名称：: 化合物 GSK1904529A

英文名称：: GSK1904529A

CAS号：: 1089283-49-7

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 99%

产品类别：: 抑制剂

货号：: T6003

Product Introduction

Bioactivity

Name	GSK1904529A
Description	GSK1904529A (GSK 4529) is a specific inhibitor of IGF-1R (IC50=27 nM) and IR(IC50=25 nM) .
Cell Research	Cells are seeded in 96-well plates and incubated overnight at 37 °C, and treated with various concentrations of GSK1904529A for 72 hours. For the NIH-3T3/LISN, cells are seeded on collagen-coated 96-well tissue culture plates and allowed to adhere for 24 hours. The tissue culture medium is replaced with serum-free medium and the cells are treated with DMSO or GSK1904529A for 2 hours. IGF-I (30 ng/mL) is added and the cells are incubated at 37 °C for 72 hours. Cell proliferation is quantified using the CellTiter-Glo Luminescent Cell Viability Assay. IC50 values are determined.
Kinase Assay	Kinase assays: GSK1904529A is dissolved in DMSO as stock solution at 10 mM. Baculovirus-expressed glutathione S-transferase-tagged proteins encoding the intracellular domain of IGF-1R (amino acids 957-1367) and IR (amino acids 979-1382) are used for determination of IC50. Kinases are activated by preincubating the enzyme (2.7 μM final concentration) in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mg/mL bovine serum albumin, and 2 mM ATP. GSK1904529A is diluted in DMSO and dispensed into the assay plates (100 nL/well). Kinase reactions contained (in 10 μL) 50 mM HEPES (pH 7.5), 3 mM DTT, 0.1 mg/mL bovine serum albumin, 1 mM CHAPS, 10 mM MgCl2, 10 μM ATP, 500 nM substrate peptide (biotin-aminohexylAEEEEYMMMMAKKKK-NH2; QPC), and 0.5 nM activated enzyme. Reactions are stopped after 1 hour at room temperature with 33 μM EDTA. Peptide phosphorylation is measured by time-resolved fluorescence resonance energy transfer with 7 nM streptavidin Surelight allophycocyanin and 1 nM europium-conjugated phosphotyrosine antibodies. Plates are read in a multilabel reader.
In vitro	GSK1904529A是一种可逆的、与ATP竞争的抑制剂，对IGF-1R和IR有很强的酶-抑制剂结合活性，其Ki值分别为1.6 nM和1.3 nM。在0.01 μM以上浓度时，能强效抑制IGF-1R和IR的配体诱导的磷酸化，进而阻断下游信号传导（AKT, IRS-1, 和 ERK）。GSK1904529A对NIH-3T3/LISN、TC-71、SK-N-MC、SK-ES RD-ES细胞具有强效抑制作用，其IC50值分别为60 nM、35 nM、43 nM、61 nM和62 nM。此外，GSK1904529A还能抑制其他多种骨髓瘤和尤因肉瘤细胞系，包括NCI-H929、MOLP-8、LP-1和KMS-12-BM等。GSK1904529A能在对GK1904529A敏感的细胞系COLO 205、MCF-7和NCI-H929中诱导细胞周期在G1期阻滞。[1]
In vivo	GSK1904529A在以30 mg/kg剂量（口服，每日两次）治疗的NIH-3T3/LISN肿瘤携带的小鼠中显示出98%的肿瘤生长抑制效果，在COLO 205异种移植小鼠中（每日一次）显示出75%的效果。在HT29和BxPC3异种移植小鼠中，以30 mg/kg剂量的GSK1904529A产生了中等程度的肿瘤生长抑制效果，且没有副作用。同时，GSK1904529A对血糖水平的影响最小。血中约3.5 μM浓度的GSK1904529A能完全抑制IGF-1R的磷酸化。GSK1904529A已被暗示用于治疗包括前列腺癌、结肠癌、乳腺癌、胰腺癌、卵巢癌和肉瘤在内的多种IGF-1R依赖型肿瘤。[1]
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 114 mg/mL (133.8 mM)
Keywords	Insulin Receptor \| Apoptosis \| Inhibitor \| anti-tumor \| GSK1904529A \| GSK4529 \| GSK-1904529A \| IGF-1R \| inhibit \| insulin \| GSK-4529
Inhibitors Related	Lidocaine hydrochloride \| Metronidazole \| 5-Fluorouracil \| Stavudine \| Tributyrin \| Dextran sulfate sodium salt (MW 4500-5500) \| Myricetin \| Sorafenib \| L-Ascorbic acid \| Acetylcysteine \| Sodium 4-phenylbutyrate \| Kaempferol
Related Compound Libraries	Inhibitor Library \| Anti-Cancer Active Compound Library \| Bioactive Compound Library \| Bioactive Compounds Library Max \| Kinase Inhibitor Library \| Fluorochemical Library \| Anti-Aging Compound Library \| Membrane Protein-targeted Compound Library \| Tyrosine Kinase Inhibitor Library \| Pain-Related Compound Library

GSK 4529|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(12年)
注册资本	566.265100万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务